Quest Partners LLC Raises Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Quest Partners LLC increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 137.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 9,410 shares of the company’s stock after buying an additional 5,449 shares during the quarter. Quest Partners LLC’s holdings in Pacira BioSciences were worth $142,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in PCRX. GAMMA Investing LLC boosted its stake in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after acquiring an additional 932 shares during the last quarter. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences in the 2nd quarter worth approximately $46,000. Innealta Capital LLC purchased a new position in Pacira BioSciences in the second quarter valued at approximately $50,000. nVerses Capital LLC lifted its stake in Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after purchasing an additional 1,600 shares during the last quarter. Finally, CWM LLC grew its holdings in Pacira BioSciences by 713.6% during the third quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after purchasing an additional 5,716 shares during the period. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Trading Down 0.8 %

Shares of PCRX stock opened at $16.64 on Friday. The business’s fifty day moving average is $16.41 and its 200 day moving average is $20.01. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company has a market capitalization of $768.27 million, a PE ratio of -8.20 and a beta of 0.82. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $35.95.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PCRX shares. Jefferies Financial Group upped their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Truist Financial lowered shares of Pacira BioSciences from a “buy” rating to a “sell” rating and cut their target price for the stock from $30.00 to $8.00 in a research report on Tuesday, August 13th. HC Wainwright lowered their price target on shares of Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Royal Bank of Canada raised their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. reissued an “underweight” rating and set a $10.00 target price (down previously from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $23.50.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.